0.509
Entero Therapeutics Inc stock is traded at $0.509, with a volume of 17.74M.
It is up +16.48% in the last 24 hours and up +0.02% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.437
Open:
$0.53
24h Volume:
17.74M
Relative Volume:
30.86
Market Cap:
$2.42M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.95%
1M Performance:
+0.02%
6M Performance:
-15.12%
1Y Performance:
+0.00%
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ENTO
Entero Therapeutics Inc
|
0.509 | 2.42M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc Stock (ENTO) Latest News
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Celiac Disease Market Expected to Experience Major Growth - openPR
Significant Contract News Sends Energy Services Company Higher - The Globe and Mail
How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail
Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail
Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag
3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail
Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive
Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail
Greif Named 2025 Gallup Exceptional Workplace Award Winner - The Globe and Mail
Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia
Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz
Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire
Vicarious Surgical names Sarah Romano as new CFO - Investing.com
3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail
Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail
Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail
Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail
Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail
Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - Cincinnati Business Courier
Onconetix names new executive chairman, appoints board member - Investing.com
iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Entero Therapeutics Appoints Richard Paolone as CEO - citybiz
AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com
Entero Therapeutics names Richard Paolone interim CEO - MSN
Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks
Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa
Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch
Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com
Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan
Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com
Entero Therapeutics Inc (ENTO) Shares Soar Above 1-Year High - The News Heater
Entero Therapeutics Appoints Three New Board Members - citybiz
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Entero Therapeutics Inc Stock (ENTO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Romano Sarah | Chief Financial Officer |
Oct 09 '24 |
Sale |
0.45 |
476 |
212 |
18,014 |
Romano Sarah | Chief Financial Officer |
Jul 02 '24 |
Sale |
1.07 |
621 |
664 |
18,490 |
SAPIRSTEIN JAMES | Chairman and CEO |
Jul 02 '24 |
Sale |
1.07 |
1,289 |
1,379 |
35,816 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):